Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

Other research analysts have also recently issued research reports about the stock. Chardan Capital reiterated a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a research note on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Stock Performance

Shares of Seres Therapeutics stock traded down $0.01 on Tuesday, hitting $0.78. 698,501 shares of the company’s stock were exchanged, compared to its average volume of 1,581,978. The company has a 50-day simple moving average of $0.84 and a 200-day simple moving average of $0.85. The stock has a market capitalization of $132.61 million, a PE ratio of -3.38 and a beta of 2.11. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $1.53.

Institutional Trading of Seres Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MCRB. Avantax Advisory Services Inc. raised its position in shares of Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 28,500 shares during the period. Jane Street Group LLC raised its position in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 37,866 shares during the period. Virtu Financial LLC raised its position in shares of Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 18,191 shares during the period. Providence Wealth Advisors LLC raised its position in shares of Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 22,250 shares during the period. Finally, Northern Trust Corp increased its holdings in Seres Therapeutics by 20.4% in the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after acquiring an additional 44,461 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.